Crossref
Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence
BJU International · 2023
DOI: 10.1111/bju.16088 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, 2023. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Kidney Calculi.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Urinary Bladder NeoplasmsCarcinoma, Transitional CellProstatic NeoplasmsKidney CalculiMaleHumansImmune Checkpoint InhibitorsHydrochlorothiazide
Substanzen
Immune Checkpoint InhibitorsHydrochlorothiazide
Zitieren
APA
(2023). Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence. BJU International. https://doi.org/10.1111/bju.16088
Vancouver
Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence. BJU International. 2023. doi:10.1111/bju.16088
BibTeX
@article{euvimed2023,
title = {Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence},
journal = {BJU International},
year = {2023},
doi = {10.1111/bju.16088}
}
EUVIMED